Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate | Zendy

Wayne Greaves | Zendy; Hong Wan | Zendy; Ka Lai Yee | Zendy; Bhargava Kandala | Zendy; Pavan Vaddady | Zendy; Carey Hwang | Zendy

Open Access

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate

Author(s) -

Wayne Greaves,

Hong Wan,

Ka Lai Yee,

Bhargava Kandala,

Pavan Vaddady,

Carey Hwang

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01298-19

Subject(s) - efavirenz , lamivudine , reverse transcriptase inhibitor , regimen , tenofovir , pharmacology , human immunodeficiency virus (hiv) , medicine , virology , sida , virus , viral load , viral disease , antiretroviral therapy , hepatitis b virus

Doravirine is a non-nucleoside reverse transcriptase inhibitor approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after stopping efavirenz. In a post-hoc subgroup analysis of participants who switched from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate in the phase 3 DRIVE-SHIFT trial, doravirine plasma levels at week 4 were similar to non-induced levels, and HIV-1 suppression was maintained at weeks 24 and 48.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research